Pfizer Will Shift Focus to Dividends and Share Buybacks, Execs Say


  • Order Reprints
  • Print Article

The big pharma company Pfizer has been on an M&A hot streak over the past couple of years, digging into its Covid-19 vaccine and therapeutic windfalls to go on a big-ticket buying spree.